Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Wednesday, 25 December 2024 ()
Company announcement – No. 53 / 2024
*Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons*
*Copenhagen, Denmark, December 25, 2024 *– Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand Pharma’s shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions.
Please see the attached file(s).
*About Zealand Pharma A/S*
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development and partnership agreements with a number of pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
*Contact:*
Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com
Anna Krassowska, PhD (Media and Investors)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com
*Attachment*
· 20241225 - Leonard Kruimer - Purchase of shares
|
||||
|
|
||||
You Might Like |
||||
